(S)-4-((2-hydroxyethyl)(naphthalen-1-ylmethyl)amino)-6-(2-methylmorpholino)pyrimidin-2(1H)-one | 1403663-10-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (S)-4-((2-hydroxyethyl)(naphthalen-1-ylmethyl)amino)-6-(2-methylmorpholino)pyrimidin-2(1H)-one
• 英文别名: 6-[2-hydroxyethyl(naphthalen-1-ylmethyl)amino]-4-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one
• CAS: 1403663-10-4
• 化学式: C₂₂H₂₆N₄O₃
• 分子量: 394.473
• InChiKey: KXFCSDGILURUCG-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  77.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-((naphthalen-1-ylmethyl)amino)ethanol 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 27.0h， 生成 (S)-4-((2-hydroxyethyl)(naphthalen-1-ylmethyl)amino)-6-(2-methylmorpholino)pyrimidin-2(1H)-one
  参考文献：
  名称：

  Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance

  摘要：

  Structure-based evolution of the original fragment leads resulted in the identification of 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, (S)-21, a potent, selective phosphoinositide 3-kinases (PI3K) p110 beta isoform inhibitor with favourable in vivo antiplatelet effect. Despite its antiplatelet action, (S)-21 did not significantly increase bleeding time in dogs. Additionally, due to its enhanced selectivity over p110 alpha, (S)-21 did not induce any insulin resistance in rats. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.102

文献信息

• SYSTEMS AND METHODS FOR PREDICTING CARDIOTOXICITY OF MOLECULAR PARAMETERS OF A COMPOUND BASED ON MACHINE LEARNING ALGORITHMS
  申请人：UTI Limited Partnership

  公开号：US20180172667A1

  公开（公告）日：2018-06-21

  Systems and methods are provided for predicting cardiotoxicity of molecular parameters of a compound. A computer can provide as input to a machine learning algorithm the molecular parameters of the compound. The molecular parameters can include at least structural information about the compound. The machine learning algorithm can have been trained using respective molecular parameters of compounds known to have cardiotoxicity and of compounds known not to have cardiotoxicity. The computer can receive as output from the machine learning algorithm a representation of the predicted cardiotoxicity of each molecular parameter of at least a subset of the molecular parameters of the compound.
• Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance
  作者：Fabrizio Giordanetto、Andreas Wållberg、Saswati Ghosal、Tommy Iliefski、Johan Cassel、Zhong-Qing Yuan、Henrik von Wachenfeldt、Søren M. Andersen、Tord Inghardt、Anders Tunek、Sven Nylander

  DOI：10.1016/j.bmcl.2012.08.102

  日期：2012.11

  Structure-based evolution of the original fragment leads resulted in the identification of 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, (S)-21, a potent, selective phosphoinositide 3-kinases (PI3K) p110 beta isoform inhibitor with favourable in vivo antiplatelet effect. Despite its antiplatelet action, (S)-21 did not significantly increase bleeding time in dogs. Additionally, due to its enhanced selectivity over p110 alpha, (S)-21 did not induce any insulin resistance in rats. (C) 2012 Elsevier Ltd. All rights reserved.